Vaxart Inc
NASDAQ:VXRT

Watchlist Manager
Vaxart Inc Logo
Vaxart Inc
NASDAQ:VXRT
Watchlist
Price: 0.8094 USD Market Closed
Market Cap: 184.1m USD
Have any thoughts about
Vaxart Inc?
Write Note
Section:
 

Relative Value

The Relative Value of one VXRT stock under the Base Case scenario is 0.7837 USD. Compared to the current market price of 0.8094 USD, Vaxart Inc is Overvalued by 3%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

VXRT Relative Value
Base Case
0.7837 USD
Overvaluation 3%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

11
P/S
P/S
Price to Sales
11
vs History
90
vs Industry
39
Median 3Y
61.3
Median 5Y
110.1
Industry
7.5
Forward
10.9
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-2.1
Median 5Y
-3.3
Industry
21.3
Forward
-2.1
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-2.6
Median 5Y
-4.6
Industry
21.6
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-2.6
Median 5Y
-3.7
Industry
23.3
More Details
2.7
P/B
P/B
Price to Book Value
2.7
vs History
65
vs Industry
42
Median 3Y
2.2
Median 5Y
3.2
Industry
2.5
More Details
7.6
EV/S
EV/S
Enterprise Value to Sales
7.6
vs History
92
vs Industry
39
Median 3Y
30.8
Median 5Y
82.7
Industry
7.4
Forward
7.6
More Details
N/A
EV/GP
EV/GP
Enterprise Value to Gross Profit
N/A
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
8.8
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
Median 3Y
-1.5
Median 5Y
-3.2
Industry
4.2
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
Median 3Y
-1.3
Median 5Y
-3.1
Industry
4
Forward
-1.6
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
Median 3Y
-1.6
Median 5Y
-3.5
Industry
6.1
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
Median 3Y
-1.6
Median 5Y
-3.2
Industry
3.9
More Details
1.2
EV/IC
EV/IC
Enterprise Value to IC
1.2
vs History
87
vs Industry
49
Median 3Y
1.9
Median 5Y
4.1
Industry
4.6
More Details

Multiples Across Competitors

VXRT Competitors Multiples
Vaxart Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Vaxart Inc
NASDAQ:VXRT
184.1m USD 11 -2.5 -2 -1.8
FR
Pharnext SCA
OTC:PNEXF
6T USD 38 519 726 -183 078.5 -222 315.6 -219 778.7
US
Abbvie Inc
NYSE:ABBV
315.4B USD 5.7 62.1 15.4 23.8
US
Amgen Inc
NASDAQ:AMGN
142B USD 4.4 33.6 16.1 30.5
US
Gilead Sciences Inc
NASDAQ:GILD
111.1B USD 3.9 881.5 9.8 9.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
106.2B USD 10 -221.4 21.9 23
US
Epizyme Inc
F:EPE
94.1B EUR 1 828.9 -466.7 -508.2 -494.7
AU
CSL Ltd
ASX:CSL
138.6B AUD 5.8 32.5 20.1 25
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
80.8B USD 5.8 17.4 15.8 17.6
US
Seagen Inc
F:SGT
39.3B EUR 17.6 -54 -58 -52.4
NL
argenx SE
XBRU:ARGX
38.2B EUR 18 -348.3 -165.7 -107.9
P/S Multiple
Revenue Growth P/S to Growth
US
Vaxart Inc
NASDAQ:VXRT
Average P/S: 3 501 967
11
32%
0.3
FR
Pharnext SCA
OTC:PNEXF
38 519 726
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.7
6%
0.9
US
Amgen Inc
NASDAQ:AMGN
4.4
8%
0.5
US
Gilead Sciences Inc
NASDAQ:GILD
3.9
3%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
10
10%
1
US
E
Epizyme Inc
F:EPE
1 828.9
N/A N/A
AU
CSL Ltd
ASX:CSL
5.8
7%
0.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.8
7%
0.8
US
S
Seagen Inc
F:SGT
17.6
30%
0.6
NL
argenx SE
XBRU:ARGX
18
47%
0.4
P/E Multiple
Earnings Growth PEG
US
Vaxart Inc
NASDAQ:VXRT
Average P/E: 205.4
Negative Multiple: -2.5 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -183 078.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
62.1
72%
0.9
US
Amgen Inc
NASDAQ:AMGN
33.6
20%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
881.5
21%
42
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -221.4
14%
N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -466.7 N/A N/A
AU
CSL Ltd
ASX:CSL
32.5
18%
1.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.4
13%
1.3
US
S
Seagen Inc
F:SGT
Negative Multiple: -54 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -348.3 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Vaxart Inc
NASDAQ:VXRT
Average EV/EBITDA: 16.5
Negative Multiple: -2 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -222 315.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.4
9%
1.7
US
Amgen Inc
NASDAQ:AMGN
16.1
18%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
9.8
5%
2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
21.9
13%
1.7
US
E
Epizyme Inc
F:EPE
Negative Multiple: -508.2 N/A N/A
AU
CSL Ltd
ASX:CSL
20.1
12%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.8
11%
1.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -58 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -165.7 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Vaxart Inc
NASDAQ:VXRT
Average EV/EBIT: 21.6
Negative Multiple: -1.8 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -219 778.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.8
24%
1
US
Amgen Inc
NASDAQ:AMGN
30.5
24%
1.3
US
Gilead Sciences Inc
NASDAQ:GILD
9.8
10%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23
13%
1.8
US
E
Epizyme Inc
F:EPE
Negative Multiple: -494.7 N/A N/A
AU
CSL Ltd
ASX:CSL
25
16%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.6
12%
1.5
US
S
Seagen Inc
F:SGT
Negative Multiple: -52.4 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -107.9 N/A N/A

See Also

Summary
VXRT intrinsic value, competitors valuation, and company profile.
DCF Valuation
VXRT stock valuation using Discount Cash Flow valuation method.
Relative Valuation
VXRT stock valuation using valuation multiples.
Wall Street Estimates
VXRT price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
VXRT stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 215,900+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.